To improve the prognosis of patients with metastatic or high-risk localized sarcoma in first CR, we explored the role of consolidation therapy with megatherapy and hematopoietic rescue. From 1986 to 1995, of 72 patients with Ewing's sarcoma from three pediatric departments, 30 were diagnosed as high-risk patients. Of these 30 patients, six did not achieve complete remission and four refused megatherapy and received multimodal treatment (chemotherapy + surgery and/or radiotherapy). The remaining 20 patients received megatherapy. There were 15 males and five females with a median age of 10.8 years (range 2-18 years). Five patients had metastatic disease at initial diagnosis, nine patients had primary tumor in the pelvis and 13 had a tumor volume greater than 100 ml. Overall disease-free survival was 62.7 ؎ 11%; 40 ؎ 21.9% for those with metastatic disease, 76.2 ؎ 12.2% for those with tumor volume greater than 100 ml and 64.8 ؎ 16.5% for those with tumor in pelvic bones. In conclusion, megatherapy has improved the outcome of this group of patients relative to that expected following conventional therapy.
Summary:
To improve the prognosis of patients with metastatic or high-risk localized sarcoma in first CR, we explored the role of consolidation therapy with megatherapy and hematopoietic rescue. From 1986 to 1995, of 72 patients with Ewing's sarcoma from three pediatric departments, 30 were diagnosed as high-risk patients. Of these 30 patients, six did not achieve complete remission and four refused megatherapy and received multimodal treatment (chemotherapy + surgery and/or radiotherapy). The remaining 20 patients received megatherapy. There were 15 males and five females with a median age of 10.8 years (range 2-18 years). Five patients had metastatic disease at initial diagnosis, nine patients had primary tumor in the pelvis and 13 had a tumor volume greater than 100 ml. Overall disease-free survival was 62.7 ؎ 11%; 40 ؎ 21.9% for those with metastatic disease, 76.2 ؎ 12.2% for those with tumor volume greater than 100 ml and 64.8 ؎ 16.5% for those with tumor in pelvic bones. In conclusion, megatherapy has improved the outcome of this group of patients relative to that expected following conventional therapy. Keywords: high-risk; Ewing's sarcoma; megatherapy; prognostic factors Ewing's sarcoma (ES) is the second most frequent bone neoplasm in children and adolescents, accounting for 10% of the total bone cancers in this age group. 1 Adjuvant chemotherapy, radiotherapy and surgery have significantly improved the prognosis for ES patients. More than 65% of patients with non-metastatic disease are long-term survivors under current protocols. [2] [3] [4] [5] On the other hand, patients with metastatic disease at the time of diagnosis and those with non-metastatic disease but with tumor localized in the pelvis or tumor volume greater than 100 ml, constitute a group of patients with very poor prognosis, [6] [7] [8] [9] although some authors consider pelvic localization as well as tumor volume greater than 100 ml to be Myeloablative radiochemotherapy followed by hematopoietic cell rescue has become a regular consolidation regimen for different pediatric high-risk solid tumors. [11] [12] [13] Adolescents and children with ES at high-risk of relapse should benefit from this new therapeutic approach.
We have evaluated the efficacy and feasibility of megatherapy plus hematopoietic cell rescue given as consolidation treatment for patients with high-risk ES in first complete remission.
Patients and methods

Patients
From 1986 to 1995, of 72 patients with Ewing's sarcoma from three pediatric departments, 30 were diagnosed as high-risk patients. Of these 30 patients, six did not achieve complete remission and four refused megatherapy and received multimodal treatment (chemotherapy + surgery and/or radiotherapy). The remaining 20 patients received megatherapy. There were 15 males and five females, with a median age of 10.8 years (range 2-18 years). These 20 patients with immunohistopathologically established ES comprised the study group. All these patients presented at least one of the following high-risk factors: (1) metastatic disease at the time of diagnosis; (2) primary tumor localized in the pelvis; and (3) tumor volume greater than 100 ml. This group of patients received myeloablative radiochemotherapy and hematopoietic stem cell autologous transplantation between 1986 and 1996. All patients underwent transplant in first complete remission. There were 15 males and five females, with a median age of 11.4 years (range 2-18 years) at the time of megatherapy. Five patients (25%) had metastatic disease at initial diagnosis; three lung and two bone metastasis. Patient characteristics are detailed in Table 1 .
Primary treatments
All patients received multimodal therapy, including surgery, radiotherapy and chemotherapy. The median interval between diagnosis and ABMT was 35 weeks (range 28-51 weeks). Treatment for primary tumor included surgery and/or radiotherapy. Eighteen patients received radio- 16 in one patient. The patients received a median of 10 courses of chemotherapy before ABMT (range 1-13 courses).
Marrow and peripheral blood stem cell (PBSC) collection and processing
Bone marrow (BM) was harvested from the iliac crests by standard techniques 17 in seven patients who had been treated between 1986 and 1992. No purging was performed. PBSC collections were performed on days +5 and +6 after granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA, USA) (12 g/kg/day) mobilization by continuous flow cell separator (Cobe Spectra, COBE, Denver, CO, USA) 18 in 13 patients who had been treated after 1993.
BM and PBSC cryopreservation and infusion
Mononuclear BM cells and PBSCs were cryopreserved with dimethylsulfoxide (l0% final concentration), frozen according to standard methods in a controlled-rate freezer (Cryoson MYC 15, Schölkrippen, Germany), and stored in liquid nitrogen until their infusion. Thawing was rapidly performed in a 37°C waterbath, and immediately infused through a central venous catheter.
Preparative regimens for transplants
Busulphan 4 mg/kg for 4 days (days Ϫ5, Ϫ4, Ϫ3 and Ϫ2) and L-PAM (melphalan) 140 mg/m 2 were administered in 12 patients, L-PAM 40 mg/m 2 for 4 days (Ϫ7, Ϫ6, Ϫ5 and Ϫ4), carboplatin 500 mg/m 2 i.v. for 3 days (days Ϫ4, Ϫ3 and Ϫ2), and VP-16 40 mg/kg for one day (day Ϫ3). Five patients received total body irradiation (12 Gy) on days Ϫ5, Ϫ4 and Ϫ3 and L-PAM 160 mg/m 2 for 1 day (day Ϫ2).
Supportive care
Marrow and PBSC transplantation were carried out in the BMT unit. A central venous catheter was placed in each patient. Patients were isolated in filtered air rooms. Prophylaxis for Pneumocystis carinii (cotrimoxazole, 8 mg/kg/day from day Ϫ7 to day 0, and then from day +50 to +150 post-transplant) and for herpes simplex virus (acyclovir 500 mg/m 2 /day from days Ϫ7 to +24) was employed. Nonabsorbable antibiotics given for gut decontamination were vancomycin, nystatin and colimycin. All hemoderived transfusion products were irradiated. G-CSF (l0 g/kg/day) was administered intravenously from day +1 until the ANC was more than l ϫ 10 9 /l for 3 consecutive days in three patients undergoing ABMT and in 13 patients undergoing PBSCT.
Definitions
Complete remission (CR) was defined as the complete resolution of all clinical and pathologic evidence of malignancy as well as any radiographic evidence of associated soft tissue masses. Disappearance of metastatic lesions in the lungs on CT scan, no evidence of tumor on BM aspirates and only residual metastatic healing lesions on 99Tc scan were necessary criteria. Non-hematological toxicity was graded by the method described by Bearman et al. 19 
Statistical methods
The software program Stata (Stata Corporation, College Station, TX, USA) was used for statistical analysis. The results are expressed in mean Ϯ standard deviation. Results were considered significant if the P value was р0.05. We estimated disease-free survival (DFS) by the Kaplan-Meier model. Finally, we compared survival among the different groups using the log-rank test.
Results
Response and survival
Disease-free survival was 62.7 Ϯ 11% (range 36.6 Ϯ 80.5%), with a mean follow-up of 26.5 Ϯ 29.3 months (7-130) (Figure 1 ).
Thirteen out of 20 patients were alive at the end of the study (December 1996), with a mean follow-up of 37.2 Ϯ 32.9 months (13-130). Survival for patients with non-metastatic disease was 70.6 Ϯ 12.6% vs 40 Ϯ 21.9% for those with metastatic disease (P = 0.08). Survival for non-metastatic patients with tumor in pelvic bones was 57.1 Ϯ 18.7% and survival for non-metastatic patients with a tumor volume greater than 100 ml was 87.5 Ϯ 11% (Figure 2) .
Seven patients died, with a mean follow-up of 7 Ϯ 5.9 months. Three of these patients had metastatic disease at diagnosis; three had tumor in pelvic bones and one had a tumor volume greater than 100 ml. Five of these seven patients died of disease progression, and two deaths were related to toxicity; one from fulminant sepsis caused by Streptococcus viridans and one from veno-occlusive hep- atic disease. Gut toxicity was mucositis grade I (12 patients), mucositis grade II (four patients). All patients had nausea and vomiting, but only one experienced grade I gastrointestinal toxicity. No other non-hematological toxicities were observed. Survival for patients conditioned with chemotherapy was 55 Ϯ 14.4% vs 80 Ϯ 17.9% for those conditioned with chemoradiotherapy (P = 0.39).
Hematopoietic recovery
The median time from transplant to a neutrophil count Ͼ0.5 ϫ 10 9 /l was 21 days (range 13-40) for ABMT patients and 11 days (range 8-13) for PBSCT patients. The median time from transplant to an unsupported platelet count Ͼ20 ϫ 10 9 /l was 25 days (range 15-72) for ABMT patients and 13 days (range 9-16) for PBSCT patients.
Discussion
Multimodal therapy has significantly improved survival for a group of ES patients. Those patients with neither gross metastatic disease at diagnosis nor bulky primary tumors of distal localization constitute a good prognosis group. However, there is another group of ES patients with a very poor clinical outcome. Adverse prognostic factors for this second group have been identified and include: tumor volume greater than 100 ml, 2,7 metastatic disease at diagnosis, 8 tumors in pelvic bones, 9 high serum LDH levels, 20 older age, 21 poor response to induction therapy 22 and soft tissue extension at diagnosis. 23 All our patients were high-risk ES patients according to the widely accepted prognostic factors:
24,25 metastatic disease at diagnosis, non-metastatic tumor with a volume greater than 100 ml, or non-metastatic tumors in pelvic bones. Conventional therapy for such patients is followed by poor clinical outcome, 26 although the Memphis team reported a favorable event-free survival following conventional therapy in metastatic ES. 27 Megatherapy with hematopoietic rescue for ES patients in first CR has not been as systematically studied as it has been for patients with neuroblastoma. 28 Studies regarding ES patients have dealt with recurrent disease, 29, 30 or multifocal primary or early relapsing ES patients. 31 There are few reported experiences with ES patients who received a transplant in first CR. 24, 25 Disease-free survival was 62.7%. However, these results must be interpreted with caution considering the number of patients with metastatic disease is smaller than that published by others, ie Ladenstein et al, 32 and the fact that all our patients were in first CR. Megatherapy for patients in second CR 33 or with refractory disease 30,34 is followed by very poor results, except in the report by Ladenstein and co-workers. 32 Based on our results, we consider the best timing for megatherapy for high-risk ES patients is at the end of conventional therapy, when the patients are in first CR.
To date, the best conditioning regimen for these patients has not yet been established. Like others, 26, 32, 35 we did not find any improvement in survival using total body irradiation, although we achieved better but not statistically significant results. A preparative regimen containing busulphan and melphalan has been reported to be effective for ES patients who underwent transplantation in first CR. 32 In summary, our results suggest that children with highrisk ES may benefit from megatherapy and hematopoietic rescue as consolidation therapy at the end of conventional treatment.
